Indica Labs Appoints a Vice President, Pharma Services
Dr. Keith J. Kaplan | July 31, 2017 | Source: Indica Labs
Indica Labs announced today that Douglas Bowman has been appointed Vice President, Pharma Services. Mr. Bowman will play an important role as the company develops its image analysis and biomarker assay services business to support preclinical and clinical biomarker assays for Indica Lab’s academic, biotech, and pharma customers.
Doug was previously at Takeda Pharmaceuticals for 11 years where he was responsible for developing quantitative biomarker assays to support the Oncology Discovery and Translational Research groups. He was a key contributor to the development of a high throughput, automated, IHC biomarker laboratory that integrated a sample management system, digital slide scanners, and quantitative image analysis into the research workflow. “I am excited at the opportunity to utilize our application expertise and industry-leading software platforms to provide image analysis and biomarker analysis services to our customers,” said Mr.Bowman. “I am confident these services will both alleviate resourcing pressure while enabling our customers to further their research and drug discovery programs by providing a better understanding of the biomarkers within the tissue environment.”
Indica Labs’ CEO, Steven Hashagen remarked, “We are delighted to welcome Doug to the team. He is recognized as a key opinion leader in the oncology biomarker domain and will be a tremendous asset to our Pharma Services team. Under his leadership we expect this strategic business unit to experience continued growth.”
About Indica Labs, Inc.
Indica Labs is a leading provider of software for quantitative evaluation of digital pathology images. Indica Lab’s HALO™ image analysis platform provides a unique combination of precision, performance, scalability, and usability which underpins a broad range of industry-leading, application-specific image analysis modules. Pharmaceutical and medical research organizations worldwide utilize HALO to support tissue-based research programs in immuno-therapy, oncology, metabolism, toxicological pathology, neuroscience and more. For additional information, please visit http://www.indicalab.com.